@entity390 and XXXX in fractionated radiotherapy: a prospective on-demand trial of tropisetron rescue for non-responders to @entity1769 .

@entity1 @entity1769 @entity391 @entity390
A prospective trial was performed to better assess the risk of @entity390 and @entity391 and the rescue value of tropisetron (TRO), a 5-HT3 receptor antagonist, in 88 @entity1 undergoing fractionated radiotherapy to the abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with @entity1769 (MET). @entity390 was graded 0 (absent), 1 (mild), 2 (moderate) and 3 (severe). @entity390 requiring anti-emetics (> or = grade 2) was present in 64% of the @entity1 . MET was able to control @entity390 (< or = grade 1) in 26 of 58 @entity1 (45%) who developed > or = grade 2 @entity390 during radiation treatment (2 @entity1 @entity391 without @entity390 included). 34 @entity1 required TRO, and 31 experienced immediate relief. However, @entity390 (> or = grade 2) recurred in 7 @entity1 from 1 to 3 weeks after starting TRO. Sex, age, field type and field size (cm2) did not influence the incidence and severity of @entity390 and @entity391 . Only 24/88 @entity1 vomited after starting radiotherapy. MET helped to eliminate emesis in one third of these @entity1 . TRO helped to control @entity391 in 73% of the salvaged @entity1 . Constipation was observed in 8 @entity1 on TRO and was a reason to stop the medication in 4 cases.
